NCT04269538View on ClinicalTrials.gov

Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

November 11, 2020

Study Completion Date

November 11, 2020

Conditions
Healthy
Interventions
DRUG

PF-06480605

PF-06480605 150 mg and 450 mg SC dosing

DRUG

Placebo

Placebo SC dosing

Trial Locations (1)

192-0071

P-one Clinic, Hachioji-shi

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Telavant, Inc.

INDUSTRY

NCT04269538 - Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants | Biotech Hunter | Biotech Hunter